Alterations in ESR1, PIK3CA, AKT1, and PTEN in HR+/HER2− MBC: Prevalence Along Treatment Course and Predictive Value for Endocrine Therapy Resistance in Real-World Practice
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice
Breast Cancer Res Treat 2024 Jun 14;[EPub Ahead of Print], MA Bhave, JCF Quintanilha, H Tukachinsky, G Li, T Scott, JS Ross, L Pasquina, RSP Huang, H McArthur, MA Levy, RP Graf, K KalinskyFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.